{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T05:07:13Z","timestamp":1784092033284,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08281-0","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T06:57:47Z","timestamp":1779346667000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-0961","authenticated-orcid":false,"given":"Valentina","family":"Doldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maura","family":"Ciniselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Aurelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Favini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio Marco","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Bozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kusamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Baratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verderio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Deraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Folini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gandellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Zaffaroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"15","key":"8281_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BWS Robinson","year":"2005","unstructured":"Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591\u2013603. https:\/\/doi.org\/10.1056\/NEJMra050152.","journal-title":"N Engl J Med"},{"issue":"3","key":"8281_CR2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3390\/cancers15030662","volume":"15","author":"S Kusamura","year":"2023","unstructured":"Kusamura S, Baratti D, De Simone M, Pasqual EM, Ansaloni L, Marrelli D, et al. Diagnostic and therapeutic pathway in Diffuse malignant peritoneal mesothelioma. Cancers. 2023;15(3):662. https:\/\/doi.org\/10.3390\/cancers15030662.","journal-title":"Cancers"},{"issue":"4","key":"8281_CR3","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in Diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1093\u2013100. https:\/\/doi.org\/10.1245\/s10434-012-2845-x.","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"8281_CR4","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"2013","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Criminol Cancer. 2013;49(15):3140\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2013.05.027.","journal-title":"Eur J Criminol Cancer"},{"issue":"11","key":"8281_CR5","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","volume":"127","author":"S Hiltbrunner","year":"2022","unstructured":"Hiltbrunner S, Fleischmann Z, Sokol ES, Zoche M, Felley-Bosco E, Curioni-Fontecedro A. Genomic landscape of pleural and peritoneal mesothelioma tumours. Br J Cancer. 2022;127(11):1997\u20132005. https:\/\/doi.org\/10.1038\/s41416-022-01979-0.","journal-title":"Br J Cancer"},{"issue":"11","key":"8281_CR6","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1002\/jcp.26830","volume":"233","author":"E Sementino","year":"2018","unstructured":"Sementino E, Menges CW, Kadariya Y, Peri S, Xu J, Liu Z, et al. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cellular Physiol. 2018;233(11):8952\u201361. https:\/\/doi.org\/10.1002\/jcp.26830.","journal-title":"J Cellular Physiol"},{"issue":"15","key":"8281_CR7","doi-asserted-by":"publisher","first-page":"13119","DOI":"10.18632\/oncotarget.3761","volume":"6","author":"M De Cesare","year":"2015","unstructured":"De Cesare M, Cominetti D, Doldi V, Lopergolo A, Deraco M, Gandellini P, et al. Anti-tumor activity of selective inhibitors of XPO1\/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 2015;6(15):13119\u201332. https:\/\/doi.org\/10.18632\/oncotarget.3761.","journal-title":"Oncotarget"},{"key":"8281_CR8","doi-asserted-by":"publisher","unstructured":"El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, et al. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10(1). https:\/\/doi.org\/10.1186\/s13045-016-0387-6.","DOI":"10.1186\/s13045-016-0387-6"},{"issue":"1","key":"8281_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"key":"8281_CR10","doi-asserted-by":"publisher","unstructured":"Vanauberg D, Schulz C, Lefebvre T. Involvement of the pro-oncogenic enzyme fatty acid synthase in the hallmarks of cancer: a promising target in anti-cancer therapies. Oncogenesis. 2023;12(1). https:\/\/doi.org\/10.1038\/s41389-023-00460-8.","DOI":"10.1038\/s41389-023-00460-8"},{"issue":"1","key":"8281_CR11","first-page":"153","volume":"7","author":"EW Gabrielson","year":"2001","unstructured":"Gabrielson EW, Pinn ML, Testa JR, Kuhajda FP. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin Cancer Res. 2001;7(1):153\u201357.","journal-title":"Clin Cancer Res"},{"key":"8281_CR12","doi-asserted-by":"crossref","unstructured":"Kim N-G, Gumbiner BM. Cell contact and Nf2\/Merlin-dependent regulation of TEAD palmitoylation and activity. Proc Natl Acad Sci. 2019: 9877\u201382, 116 (20).","DOI":"10.1073\/pnas.1819400116"},{"issue":"6","key":"8281_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.devcel.2022.02.004","volume":"57","author":"S Vaidyanathan","year":"2022","unstructured":"Vaidyanathan S, Salmi TM, Sathiqu RM, McConville MJ, Cox AG, Brown KK. YAP regulates an SGK1\/mTORC1\/SREBP-dependent lipogenic program to support proliferation and tissue growth. Dev Cell. 2022;57(6):719\u201331.e8. https:\/\/doi.org\/10.1016\/j.devcel.2022.02.004.","journal-title":"Dev Cell"},{"issue":"1","key":"8281_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-016-0387-6","volume":"10","author":"R El Bezawy","year":"2017","unstructured":"El Bezawy R, De Cesare M, Pennati M, Deraco M, Gandellini P, Zuco V, et al. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism. J Hematol Oncol. 2017;10(1):19. https:\/\/doi.org\/10.1186\/s13045-016-0387-6.","journal-title":"J Hematol Oncol"},{"issue":"13","key":"8281_CR15","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/bioinformatics\/btn224","volume":"24","author":"P Du","year":"2008","unstructured":"Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24(13):1547\u201348. https:\/\/doi.org\/10.1093\/bioinformatics\/btn224.","journal-title":"Bioinformatics"},{"issue":"13","key":"8281_CR16","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1245\/s10434-015-4498-z","volume":"22","author":"M Deraco","year":"2015","unstructured":"Deraco M, Cabras A, Baratti D, Kusamura S. Immunohistochemical evaluation of Minichromosome maintenance protein 7 (MCM7), topoisomerase II\u03b1, and Ki-67 in Diffuse malignant peritoneal mesothelioma patients using tissue microarray. Ann Surg Oncol. 2015;22(13):4344\u201351. https:\/\/doi.org\/10.1245\/s10434-015-4498-z.","journal-title":"Ann Surg Oncol"},{"issue":"46","key":"8281_CR17","doi-asserted-by":"publisher","first-page":"75503","DOI":"10.18632\/oncotarget.12262","volume":"7","author":"F Bozzi","year":"2016","unstructured":"Bozzi F, Brich S, Dagrada GP, Negri T, Conca E, Cortelazzi B, et al. Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial\/epithelial-mesenchymal transition framework. Oncotarget. 2016;7(46):75503\u201317. https:\/\/doi.org\/10.18632\/oncotarget.12262.","journal-title":"Oncotarget"},{"issue":"13","key":"8281_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jnci\/djh184","volume":"96","author":"G Cuccuru","year":"2004","unstructured":"Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-Associated medullary thyroid carcinoma. JNCI J Natl Cancer Inst. 2004;96(13):1006\u201314. https:\/\/doi.org\/10.1093\/jnci\/djh184.","journal-title":"JNCI J The Natl Cancer Inst"},{"issue":"282","key":"8281_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457\u201381. https:\/\/doi.org\/10.1080\/01621459.1958.10501452.","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"8281_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and Life-Tables. J R Stat Soc Ser B Stat Methodol. 1972;34(2):187\u2013202. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"10","key":"8281_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","volume":"30","author":"H Uno","year":"2011","unstructured":"Uno H, Cai T, Pencina MJ, D\u2019Agostino RB, Wei LJ. On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med. 2011;30(10):1105\u201317. https:\/\/doi.org\/10.1002\/sim.4154.","journal-title":"Stat Med"},{"issue":"13","key":"8281_CR22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s40265-019-01188-9","volume":"79","author":"YY Syed","year":"2019","unstructured":"Syed YY. Selinexor: first global approval. Drugs. 2019;79(13):1485\u201394. https:\/\/doi.org\/10.1007\/s40265-019-01188-9.","journal-title":"Drugs"},{"issue":"2","key":"8281_CR23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u201346. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947.","journal-title":"Cancer Res"},{"issue":"12","key":"8281_CR24","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1245\/s10434-023-13973-8","volume":"30","author":"V Kepenekian","year":"2023","unstructured":"Kepenekian V, Sgarbura O, Marchal F, Villeneuve L, Kusamura S, Deraco M. 2022 PSOGI Consensus on HIPEC Regimens for peritoneal Malignancies: diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2023;30(12):7803\u201313. https:\/\/doi.org\/10.1245\/s10434-023-13973-8.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"8281_CR25","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/pharmaceutics14061303","volume":"14","author":"C Navarro","year":"2022","unstructured":"Navarro C, Ortega \u00c1, Santeliz R, Garrido B, Chac\u00edn M, Galban N, et al. Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches. Pharmaceutics. 2022;14(6):1303. https:\/\/doi.org\/10.3390\/pharmaceutics14061303.","journal-title":"Pharmaceutics"},{"issue":"3","key":"8281_CR26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/1878-0261.13582","volume":"18","author":"JA Menendez","year":"2024","unstructured":"Menendez JA, Cuy\u00e0s E, Encinar JA, Vander Steen T, Verdura S, Llop-Hern\u00e1ndez \u00c0, et al. Fatty acid synthase (FASN) signalome: a molecular guide for precision oncology. Mol Oncol. 2024;18(3):479\u2013516. https:\/\/doi.org\/10.1002\/1878-0261.13582.","journal-title":"Mol Oncol"},{"key":"8281_CR27","doi-asserted-by":"crossref","unstructured":"Karnan S, Ota A, Hasan MN, Murakami H, Rahman ML, Wahiduzzaman M, et al. Targeting fatty acid synthase suppresses tumor development in NF2\/CDKN2A-deficient malignant pleural mesothelioma. 2024.","DOI":"10.1101\/2024.07.14.603191"},{"issue":"3","key":"8281_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","volume":"20","author":"AM Heck","year":"2000","unstructured":"Heck AM, Yanovski JA, Calis KA. Orlistat, a New lipase inhibitor for the management of obesity. Pharmacother: J Hum Pharmacol Drug Ther. 2000;20(3):270\u201379. https:\/\/doi.org\/10.1592\/phco.20.4.270.34882.","journal-title":"Pharmacother: J Hum Pharmacol Drug Ther"},{"issue":"3","key":"8281_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1128\/br.40.3.681-697.1976","volume":"40","author":"S Omura","year":"1976","unstructured":"Omura S. The antibiotic cerulenin, a novel tool for biochemistry as an inhibitor of fatty acid synthesis. Bacteriol Rev. 1976;40(3):681\u201397. https:\/\/doi.org\/10.1128\/br.40.3.681-697.1976.","journal-title":"Bacteriol Rev"},{"key":"8281_CR30","doi-asserted-by":"crossref","unstructured":"Kuhajda FP, Pizer ES, Li JN, Mani NS, Frehywot GL, Townsend CA. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proceedings of the National Academy of Sciences. 2000: 3450\u201354, 97 (7).","DOI":"10.1073\/pnas.97.7.3450"},{"key":"8281_CR31","doi-asserted-by":"publisher","first-page":"100797","DOI":"10.1016\/j.eclinm.2021.100797","volume":"34","author":"G Falchook","year":"2021","unstructured":"Falchook G, Infante J, Arkenau H-T, Patel MR, Dean E, Borazanci E, et al. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021;34:100797. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100797.","journal-title":"EClinicalMedicine"},{"key":"8281_CR32","unstructured":"https:\/\/www.clinicaltrials.gov\/study\/NCT03179904."},{"issue":"4","key":"8281_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/hep.32359","volume":"76","author":"H Wang","year":"2022","unstructured":"Wang H, Zhou Y, Xu H, Wang X, Zhang Y, Shang R, et al. Therapeutic efficacy of FASN inhibition in preclinical models of HCC. Hepatology. 2022;76(4):951\u201366. https:\/\/doi.org\/10.1002\/hep.32359.","journal-title":"Hepatology"},{"key":"8281_CR34","doi-asserted-by":"publisher","first-page":"104910","DOI":"10.1016\/j.critrevonc.2025.104910","volume":"214","author":"PV Nuzzo","year":"2025","unstructured":"Nuzzo PV, Rodrigues S, Ribeiro CF, Teixeira IF, Fanelli GN, Bleve S, et al. Targeting cancer metabolism: therapeutic potential of the fatty acid synthase (FASN) inhibitors. Crit Rev Oncol\/Hematol. 2025;214:104910. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104910.","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"4","key":"8281_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nchembio.2036","volume":"12","author":"P Chan","year":"2016","unstructured":"Chan P, Han X, Zheng B, Deran M, Yu J, Jarugumilli GK, et al. Autopalmitoylation of TEAD proteins regulates transcriptional output of the Hippo pathway. Nat Chem Biol. 2016;12(4):282\u201389. https:\/\/doi.org\/10.1038\/nchembio.2036.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"8281_CR36","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.str.2015.11.005","volume":"24","author":"C Noland","year":"2016","unstructured":"Noland C, Gierke S, Schnier P, Murray J, Sandoval W, Sagolla M, et al. Palmitoylation of TEAD transcription factors is required for their stability and function in Hippo pathway Signaling. Structure. 2016;24(1):179\u201386. https:\/\/doi.org\/10.1016\/j.str.2015.11.005.","journal-title":"Structure"},{"issue":"7","key":"8281_CR37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA, Sansregret L, Galli GG, Ch\u00e8ne P, Wartmann M, Mourikis TP, et al. Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013mAPK-altered cancers. Nat Cancer. 2024;5(7):1102\u201320. https:\/\/doi.org\/10.1038\/s43018-024-00754-9.","journal-title":"Nat Cancer"},{"key":"8281_CR38","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04857372."},{"key":"8281_CR39","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT01607905."}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08281-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:38:31Z","timestamp":1784090311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08281-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8281"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08281-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8641233\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and all patients provided written informed consent to donate biological material for research purposes and the study was approved by the Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori (INT) (ID:INT 84\/15).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have approved the final version of the manuscript and agree to its publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Authors reported no conflict of interest for the conduction of this study.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"911"}}